Dorflinger E., Yoo K., Morawsky L. and Fazzini E. (1993) Monoamine
oxidase B (MAO B) inhibitor therapy in Parkinson's disease: Degree
and reversibility of human brain MAO B inhibition by Ro 19 6327.
Neurology 43, 1984 –1992. 13.
7. Jovanovic-Micic D., Samardzic R. and Beleslin D. B. (1995) The role of
alpha-adrenergic mechanisms within the area postrema in dopamineinduced emesis. Eur. J. Pharmacol. 272, 21–30.
8. Konradi C., Svoma E., Jellinger K., Riederer P., Denney P. and Thibault 14.
J. (1988) Topographic immunocytochemical mapping of monoamine
oxidase A, monoamine oxidase B and tyrosine hydroxylase in human
post mortem brain stem. Neuroscience 26, 791– 802.
9. MacGregor R. R., Halldin C., Fowler J. S., Wolf A. P., Arnett C. D.,
15.
Langstrom B. and Alexoff D. (1985) Selective, irreversible in vivo
binding of [11C]clorgyline and [11C]-L-deprenyl in mice: Potential for
measurement of functional monoamine oxidase activity in brain using
16.
positron emission tomography. Biochem. Pharmacol. 34, 3207–3210.
10. Miselis R. R., Shapiro R. E. and Hyde T. M. (1987) The area postrema.
In: Circumventriculargans and Body Fluids, Vol. II (Edited by Gross P.),
pp. 185–207. CRC Press, Boca Raton, FL. 17.
11. Munson P. J. and Rodbard D. (1980) LIGAND: A versatile approach
for the characterisation of ligand binding systems. Anal. Biochem. 107,
220 –239. 18.
Plenevaux A., Dewey S. L., Fowler J. S., Guillaume M. and Wolf A. P.
(1990) Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-
